Trazodone Manufacturing, Supply & Shortage History

How Trazodone Works: Mechanism of Action

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that blocks 5-HT2A receptors and inhibits the serotonin transporter. At low doses (25-100 mg), the 5-HT2A antagonism and histamine H1 receptor blockade predominate, producing sedation without significant serotonin reuptake inhibition [1]. This pharmacologic profile explains why the drug found its largest clinical niche as a sleep aid rather than an antidepressant.

The antidepressant effect requires higher doses (150-600 mg/day), where serotonin transporter inhibition becomes clinically meaningful. Trazodone also antagonizes alpha-1 adrenergic receptors, contributing to orthostatic hypotension but adding another sedative mechanism [2]. Its short half-life of 5-9 hours means minimal next-day hangover at sleep-promoting doses, a pharmacokinetic advantage over longer-acting alternatives like doxepin at higher doses.

Mendelson's 2005 review in the Journal of Clinical Psychiatry noted that trazodone had become the most commonly prescribed agent for insomnia in the United States despite limited randomized controlled trial support for that indication [3]. That prescribing pattern persists two decades later and directly shapes the drug's demand profile and supply requirements.

The Generic Manufacturing Base

Trazodone lost patent protection in 1986. The original brand, Desyrel (manufactured by Bristol-Myers Squibb, later Apothecon), was discontinued as generics captured the market entirely.

Today, the FDA's Orange Book lists more than 12 approved Abbreviated New Drug Applications (ANDAs) for trazodone hydrochloride tablets [4]. Major manufacturers supplying the US market include Teva Pharmaceutical, Zydus Pharmaceuticals (formerly Cadila), Aurobindo Pharma, Sun Pharmaceutical, Apotex, Mylan (now Viatris), Amneal Pharmaceuticals, and Torrent Pharma. Each holds approval for one or more tablet strengths.

The active pharmaceutical ingredient (API) is synthesized primarily in facilities located in India and Italy. Trazodone's chemical structure (a triazolopyridine derivative) requires a multi-step synthesis involving chlorophenyl piperazine intermediates. The concentration of API production in a limited number of facilities creates a supply bottleneck that has triggered shortages when even one major supplier encounters manufacturing problems.

FDA Shortage History: A Timeline

The FDA Drug Shortage Database documents multiple trazodone shortage events since systematic tracking began. Each episode reveals a different vulnerability in the supply chain.

2012-2013: First major generic shortage. Multiple manufacturers reported manufacturing delays simultaneously. The FDA listed trazodone 50 mg and 100 mg tablets as unavailable from several suppliers. Root cause: API supply disruption from a key Indian facility undergoing remediation after an FDA warning letter [5].

2015: Demand-driven tightness. As insomnia prescribing continued to grow (trazodone prescriptions increased 12% year-over-year from 2013 to 2015 per IQVIA data), certain manufacturers could not scale production quickly enough. The 50 mg strength experienced allocation limits at wholesale distributors.

2019: Brief supply interruption. Aurobindo Pharma reported temporary unavailability of its 50 mg product due to packaging line maintenance. The shortage resolved within 8 weeks as other manufacturers increased output.

2020-2021: COVID-era disruptions. The pandemic created a dual pressure: increased demand (insomnia and anxiety prescriptions rose sharply during COVID-19 lockdowns) and disrupted international API shipping. The American Society of Health-System Pharmacists (ASHP) listed trazodone among drugs experiencing intermittent supply constraints during this period [6].

2023: Spot shortages at 150 mg and 300 mg. Higher-strength tablets, used primarily for depression rather than sleep, experienced limited availability from select manufacturers. The FDA attributed this to "increased demand" and "manufacturing delays" in its shortage database entry.

Why Trazodone Is Vulnerable to Shortages

Three structural factors make trazodone's supply chain fragile despite having many generic manufacturers.

Low margins discourage inventory buffers. Generic trazodone 50 mg costs approximately $0.03-0.08 per tablet at wholesale. At these price points, manufacturers operate on thin margins and maintain minimal safety stock. A 2019 analysis published in the Journal of the American Medical Association found that drugs priced below $0.10 per unit experienced shortage rates 2.5 times higher than drugs priced above $1.00 per unit [7].

API concentration risk. Although multiple finished-dose manufacturers exist, the upstream API supply relies on fewer than five major producers globally. When one facility goes offline for regulatory remediation or maintenance, downstream tablet manufacturers all compete for limited remaining API inventory.

Demand volatility from off-label use. Because trazodone's largest use case (insomnia) is off-label, demand patterns do not follow the predictable trajectories of on-label indications. Seasonal sleep disruption, pandemic anxiety, and shifts in prescriber preference (such as movement away from Z-drugs after FDA boxed warning updates) can produce sudden demand spikes that outpace production planning.

The Oleptro Chapter: Extended-Release Rise and Fall

In 2010, the FDA approved Oleptro, a once-daily extended-release formulation of trazodone (150 mg and 300 mg tablets) manufactured by Angelini Pharma for the treatment of major depressive disorder [8]. The product used Contramid technology to deliver trazodone over a longer period, theoretically improving tolerability and antidepressant efficacy.

Oleptro was discontinued in 2016 due to commercial failure. It never achieved significant market share. Clinicians continued prescribing immediate-release generic trazodone, and payers resisted covering a branded reformulation of a $4 generic. The discontinuation left no extended-release trazodone product on the US market.

This commercial failure illustrates a broader dynamic: when a drug is so cheap in generic form that branded reformulations cannot compete, the entire supply depends on generic manufacturers who face relentless price erosion. No company has financial incentive to invest in supply chain redundancy.

Current Manufacturing and Quality Oversight

The FDA inspects trazodone manufacturing facilities under its routine drug quality surveillance program. Between 2018 and 2024, several API facilities in India received Form 483 observations related to data integrity, cleaning validation, and stability testing deficiencies [9]. None resulted in product recalls, but inspection findings at API facilities historically precede supply tightening by 6-18 months as companies undertake voluntary remediation.

Finished-dose manufacturers in the US must comply with current Good Manufacturing Practice (cGMP) regulations. The Drug Quality and Security Act of 2013 strengthened FDA authority to address manufacturing quality issues, but the agency's ability to prevent shortages remains limited when root causes are economic rather than regulatory.

The CARES Act of 2020 added requirements for manufacturers to notify FDA of potential supply disruptions 6 months in advance. Early evidence suggests this has improved FDA's ability to coordinate responses but has not prevented shortages from occurring [10].

Clinical Implications of Supply Disruption

When trazodone becomes unavailable, clinicians face substitution decisions that carry clinical risk. For sleep-indication patients, alternatives include:

Low-dose doxepin (Silenor, 3-6 mg) is FDA-approved for insomnia but costs significantly more. Suvorexant (Belsomra) and lemborexant (Dayvigo) target orexin receptors with different safety profiles. Hydroxyzine offers antihistaminic sedation but lacks trazodone's serotonergic activity. Gabapentin is sometimes substituted but carries its own supply constraints and misuse potential.

For depression-indication patients on higher doses, switching within the antidepressant class requires careful cross-titration. The Endocrine Society and American Psychiatric Association do not provide specific guidance on trazodone shortage management, leaving clinicians to apply general switching principles [11].

A 2022 survey published in the Journal of Managed Care & Specialty Pharmacy found that 34% of pharmacists reported having to contact prescribers about trazodone unavailability at least once monthly during active shortage periods [12]. Each intervention consumes clinician time and risks patient non-adherence during the transition.

Prescribing Volume and Demand Trends

IQVIA National Prescription Audit data show trazodone consistently ranks among the top 30 most-dispensed medications in the United States. In 2023, approximately 26 million prescriptions were dispensed, a figure that has grown steadily from 22 million in 2018 [13].

This growth is driven almost entirely by sleep-indication prescribing. The American Academy of Sleep Medicine's 2017 clinical practice guideline listed trazodone among medications with insufficient evidence to recommend for chronic insomnia, yet real-world prescribing has not decreased [14]. Prescribers cite its favorable side-effect profile compared to benzodiazepines, non-scheduled status (no DEA classification), and negligible cost as reasons for continued preference.

The disconnect between guideline evidence and prescribing volume means demand forecasting models used by manufacturers may underestimate true utilization. When multiple health systems simultaneously increase trazodone formulary use (as occurred when several VA medical centers shifted from zolpidem to trazodone in 2019-2020), the supply chain cannot adapt quickly.

International Supply Context

Trazodone supply dynamics differ outside the United States. In the European Union, Angelini Pharma remains a major supplier under brand names including Trittico. Italy has a more concentrated supply base with less shortage frequency, partly because single-source branded products maintain higher prices that incentivize inventory investment.

In Canada, trazodone experienced shortages in 2020 and 2022, tracked by Health Canada's Drug Shortage Database. The Canadian market depends on many of the same API suppliers as the US, creating correlated shortage risk across North American markets.

Australia's Therapeutic Goods Administration (TGA) lists trazodone as available from two suppliers. The smaller supplier base makes the Australian market more vulnerable to single-manufacturer disruptions [15].

What Prescribers Should Know

Three practical steps reduce patient impact during trazodone supply disruptions.

First, maintain an active therapeutic alternative plan for sleep-indication patients. Document a patient-specific second-line agent in the chart so that pharmacy staff can support rapid switching without requiring a new clinical encounter.

Second, prescribe the 100 mg tablet with instructions to split for 50 mg doses when 50 mg tablets are unavailable. The 100 mg strength has historically experienced fewer shortages because multiple manufacturers prioritize it.

Third, monitor the FDA Drug Shortage Database and ASHP shortage notifications proactively. Supply constraints typically worsen over 4-8 weeks before resolving, giving clinics time to identify affected patients and prepare alternatives.

The FDA recommends that healthcare providers report shortage-related patient harm through MedWatch to help quantify the clinical impact of drug unavailability and justify regulatory interventions [16].

Regulatory and Policy Responses

The US Government Accountability Office (GAO) has published multiple reports examining drug shortage root causes. A 2016 GAO report identified economic factors (low generic drug prices reducing manufacturer incentive to maintain excess capacity) as the primary structural driver of generic drug shortages [17]. Trazodone exemplifies this pattern precisely.

Policy proposals to address generic drug shortages include: government strategic reserves for essential medications, minimum viable inventory requirements for manufacturers, and value-based pricing floors that ensure manufacturers can maintain quality and supply reliability. None have been enacted as of 2026.

The Drug Shortage Prevention Act, introduced in Congress in 2023, would require manufacturers to maintain 6-month safety stock for drugs with fewer than three active suppliers. If enacted, trazodone (with 12+ suppliers) would likely be exempt, highlighting the gap between policy frameworks designed for single-source drugs and the reality of shortages affecting multi-source generics.

Trazodone 50 mg tablets remain available from at least 8 manufacturers as of May 2026, with no active FDA shortage listing for any strength.